NCT03653507 2026-04-17GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 3 FDA
NCT03675737 2026-02-27KEYNOTE-859Merck Sharp & Dohme LLCPhase 3 Completed1,579 enrolled 31 charts 2 FDA
NCT05104866 2026-02-04A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)AstraZenecaPhase 3 Active not recruiting732 enrolled 22 charts 3 FDA
NCT03615326 2025-12-11MK-3475-811Merck Sharp & Dohme LLCPhase 3 Completed738 enrolled 22 charts 7 FDA
NCT03734029 2025-10-06Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]Daiichi SankyoPhase 3 Active not recruiting557 enrolled 22 charts 2 FDA
NCT04607421 2025-08-14A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPfizerPhase 3 Active not recruiting831 enrolled 5 FDA
NCT02872116 2025-08-07CheckMate649Bristol-Myers SquibbPhase 3 Completed2,031 enrolled 19 charts 2 FDA